Regeneron bids for 23andMe at a discounted price of $256 million. The testing firm was once valued at $3.5 billion.

Genetics company 23andMe is expected to be purchased by Regeneron Pharmaceuticals, according to announcements shared by both ...

Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never ...

Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology, ASH, 2024 Annual Meeting ...

At Regeneron, we have spent over three decades honing a deep expertise in disease biology and genetics. By rigorously pursuing an understanding of pathobiology—the mechanisms by which diseases ...

She has been working in journalism for seven years. Justin Sullivan/Getty; Michael Nagle/Bloomberg via Getty Regeneron Pharmaceuticals plans to purchase 23andMe just two months after the ...